Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 01NVF19002 | Other Grant/Funding Number | Gemeinsamer Bundesausschuss; Innovationsausschuss |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| privates Institut für angewandte Versorgungsforschung GmbH | UNKNOWN |
| AOK PLUS | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy of an online platform that allows neurologists and therapists to exchange therapy recommendations, communicate assessments and plan physical therapy, occupational therapy as well as speech and swallowing therapy for their patients.
The aim of this study is to enroll 185 patients in the intervention group and 185 patients in the control group. Patients in the intervention group come from the same region (Münsterland), the control group will consist of patients outside this region. The patients in the intervention group undergo therapies planned and coordinated through the online platform for 12 months. The patients in the intervention group will be evaluated using the PDQ-39, UPDRS, H&Y as well as Schwab & England. The patients in the control group will be evaluated using the PDQ-39.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention group | Active Comparator | Patients in the intervention group come from the same region (Münsterland) and will undergo therapies coordinated through the online platform. |
|
| Control group | No Intervention | Patients in the control group will undergo their usual therapies as prescribed by their neurologists. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Coordination through the online platform "JamesAKTIV" | Other | Coordination of the treatment through the online platform "JamesAKTIV" that allows neurologists and therapists to select specialised therapies for the predominant symptoms of the patients and communicate easily about problems during the treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Quality of Life measured by PDQ 39 | The Parkinson's Disease Questionnaire (PDQ-39, max. score of 100 indicates the worst quality of life) | Change from Baseline PDQ 39 at 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Health-related resource use in the elderly population, assessed by FIMA | FIMA stands for "Questionnaire concerning Health-related resource use in the elderly population" and is a German questionnaire assessing the Health-related resource use in the elderly population | Change from Baseline FIMA at 12 months |
Not provided
Inclusion Criteria (Intervention Group):
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tessa Huchtemann, Medical Degree | Contact | 004915254956565 | Tessa.Huchtemann@ukmuenster.de | |
| Tobias Warnecke, Medical Degree, PhD | Contact | 00492518345314 | Tobias.Warnecke@ukmuenster.de |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universitätsklinikum Münster, Klinik für Neurologie | Recruiting | Münster | North Rhine-Westphalia | 48149 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37259124 | Derived | Achtert K, Huchtemann T, Altendorf M, Kerkemeyer L, Haring M, Lummer C, Frenz L, Becking T, Friedmann J, Mildner P, Schwarze K, Steinhaus L, Amelung V, Warnecke T. Design and implementation of ParkinsonAKTIV: an interventional study to evaluate the effectiveness of a novel online platform to guide quickcard-based treatment decisions. Neurol Res Pract. 2023 Jun 1;5(1):23. doi: 10.1186/s42466-023-00249-5. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Change in disease severity measured by UPDRS |
UPDRS - Unified Parkinson's Disease Rating Scale, max. score of 199 points indicates the worst outcome |
| Change from Baseline UPDRS at 12 months |
| Change in disease severity measured by Hoehn & Yahr | Hoehn & Yahr is a simple scale that describes disease severity on a scale of 0-5, with 5 indicating severe disability | Change from Baseline UPDRS at 12 months |
| Change in mobility, measured by Schwab- & England-Scale | Schwab- & England-Scale assesses the capabilities of people with impaired mobility. The scale uses percentages with 100% indicating full independence. | Change from Baseline Schwab-&England-Scale at 12 months |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |